You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Type 1 Issues Articles
Popular Type 1 Issues Articles
Highly Recommended Type 1 Issues Articles
Send a link to this page to your friends and colleagues.
So close, and yet so far. It looks like there will be no marketing partnership for MannKind's ultra rapid-acting insulin product Afresa anytime soon. The company had planned to enter into a deal with a large pharmaceutical company by the end of this year, but now approval from the Food and Drug Administration (FDA) for their inhaled insulin won't be until January 2010, at the earliest.
"We believe that we and our potential partners will be better able to address appropriate deal terms and structure once the label for AFRESA is clarified. Since we do not expect a response from the FDA before January 2010, we believe that we will not conclude a deal before the end of 2009", says MannKind Corp in a regulatory filing dated Tuesday October 6, 2009.
Shares of the company's stock have taken a nosedive.
Considering the first FDA-approved inhaled insulin, Exubera, was pulled from the market because of poor sales, it will be very interesting to see just how successful Afresa may be. MannKind believes that their product's unique formulation, which alters the pharmacokinetics and pharmacodynamics of the drug as compared to previous attempts at inhaled insulin, puts them in a different category altogether. But for now, don't hold your breath.
* * *
Securities and Exchange Commission Regulatory Filing
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.